572 related articles for article (PubMed ID: 26589966)
21. Uncoupling, metabolic inhibition and induction of mitochondrial permeability transition in rat liver mitochondria caused by the major long-chain hydroxyl monocarboxylic fatty acids accumulating in LCHAD deficiency.
Hickmann FH; Cecatto C; Kleemann D; Monteiro WO; Castilho RF; Amaral AU; Wajner M
Biochim Biophys Acta; 2015; 1847(6-7):620-8. PubMed ID: 25868874
[TBL] [Abstract][Full Text] [Related]
22. De novo fatty acid biosynthesis and elongation in very long-chain acyl-CoA dehydrogenase-deficient mice supplemented with odd or even medium-chain fatty acids.
Tucci S; Behringer S; Spiekerkoetter U
FEBS J; 2015 Nov; 282(21):4242-53. PubMed ID: 26284828
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening.
Spiekerkoetter U
J Inherit Metab Dis; 2010 Oct; 33(5):527-32. PubMed ID: 20449660
[TBL] [Abstract][Full Text] [Related]
24. Long-chain 3-hydroxy fatty acids accumulating in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial trifunctional protein deficiencies uncouple oxidative phosphorylation in heart mitochondria.
Tonin AM; Amaral AU; Busanello EN; Grings M; Castilho RF; Wajner M
J Bioenerg Biomembr; 2013 Feb; 45(1-2):47-57. PubMed ID: 23065309
[TBL] [Abstract][Full Text] [Related]
25. Altered Metabolic Flexibility in Inherited Metabolic Diseases of Mitochondrial Fatty Acid Metabolism.
Tucci S; Alatibi KI; Wehbe Z
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33917608
[TBL] [Abstract][Full Text] [Related]
26. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders.
Djouadi F; Bastin J
J Inherit Metab Dis; 2008 Apr; 31(2):217-25. PubMed ID: 18392740
[TBL] [Abstract][Full Text] [Related]
27. Disorders of mitochondrial fatty acyl-CoA beta-oxidation.
Wanders RJ; Vreken P; den Boer ME; Wijburg FA; van Gennip AH; IJlst L
J Inherit Metab Dis; 1999 Jun; 22(4):442-87. PubMed ID: 10407780
[TBL] [Abstract][Full Text] [Related]
28. Intestinal pseudo-obstruction as a manifestation of impaired mitochondrial fatty acid oxidation.
Gilbert J; Ibdah JA
Med Hypotheses; 2005; 64(3):586-9. PubMed ID: 15617873
[TBL] [Abstract][Full Text] [Related]
29. Cardiologic evaluation of Turkish mitochondrial fatty acid oxidation disorders.
Balci MC; Karaca M; Ergul Y; Omeroglu RE; Demirkol M; Gokcay GF
Pediatr Int; 2022 Jan; 64(1):e15317. PubMed ID: 36331231
[TBL] [Abstract][Full Text] [Related]
30. Living on the edge: substrate competition explains loss of robustness in mitochondrial fatty-acid oxidation disorders.
van Eunen K; Volker-Touw CM; Gerding A; Bleeker A; Wolters JC; van Rijt WJ; Martines AM; Niezen-Koning KE; Heiner RM; Permentier H; Groen AK; Reijngoud DJ; Derks TG; Bakker BM
BMC Biol; 2016 Dec; 14(1):107. PubMed ID: 27927213
[TBL] [Abstract][Full Text] [Related]
31. Bile acylcarnitine profiles in pediatric liver disease do not interfere with the diagnosis of long-chain fatty acid oxidation defects.
Fuda F; Narayan SB; Squires RH; Bennett MJ
Clin Chim Acta; 2006 May; 367(1-2):185-8. PubMed ID: 16414039
[TBL] [Abstract][Full Text] [Related]
32. The Biochemistry and Physiology of Mitochondrial Fatty Acid β-Oxidation and Its Genetic Disorders.
Houten SM; Violante S; Ventura FV; Wanders RJ
Annu Rev Physiol; 2016; 78():23-44. PubMed ID: 26474213
[TBL] [Abstract][Full Text] [Related]
33. Influence of dietary fatty acid chain-length on metabolic tolerance in mouse models of inherited defects in mitochondrial fatty acid beta-oxidation.
Schuler AM; Gower BA; Matern D; Rinaldo P; Wood PA
Mol Genet Metab; 2004 Dec; 83(4):322-9. PubMed ID: 15589119
[TBL] [Abstract][Full Text] [Related]
34. Oxidative damage in mitochondrial fatty acids oxidation disorders patients and the in vitro effect of l-carnitine on DNA damage induced by the accumulated metabolites.
de Moraes MS; Guerreiro G; Sitta A; de Moura Coelho D; Manfredini V; Wajner M; Vargas CR
Arch Biochem Biophys; 2020 Jan; 679():108206. PubMed ID: 31760122
[TBL] [Abstract][Full Text] [Related]
35. Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay.
Yamaguchi S; Li H; Purevsuren J; Yamada K; Furui M; Takahashi T; Mushimoto Y; Kobayashi H; Hasegawa Y; Taketani T; Fukao T; Fukuda S
Mol Genet Metab; 2012 Sep; 107(1-2):87-91. PubMed ID: 22841441
[TBL] [Abstract][Full Text] [Related]
36. ACAD9, a complex I assembly factor with a moonlighting function in fatty acid oxidation deficiencies.
Nouws J; Te Brinke H; Nijtmans LG; Houten SM
Hum Mol Genet; 2014 Mar; 23(5):1311-9. PubMed ID: 24158852
[TBL] [Abstract][Full Text] [Related]
37. Modeling disorders of fatty acid metabolism in the mouse.
Goetzman ES
Prog Mol Biol Transl Sci; 2011; 100():389-417. PubMed ID: 21377632
[TBL] [Abstract][Full Text] [Related]
38. Dynamic simulations on the mitochondrial fatty acid beta-oxidation network.
Modre-Osprian R; Osprian I; Tilg B; Schreier G; Weinberger KM; Graber A
BMC Syst Biol; 2009 Jan; 3():2. PubMed ID: 19126203
[TBL] [Abstract][Full Text] [Related]
39. Impairment of mitochondrial bioenergetics and permeability transition induction caused by major long-chain fatty acids accumulating in VLCAD deficiency in skeletal muscle as potential pathomechanisms of myopathy.
Cecatto C; Amaral AU; Roginski AC; Castilho RF; Wajner M
Toxicol In Vitro; 2020 Feb; 62():104665. PubMed ID: 31629068
[TBL] [Abstract][Full Text] [Related]
40. In vivo stable isotope studies in three patients affected with mitochondrial fatty acid oxidation disorders: limited diagnostic use of 1-13C fatty acid breath test using bolus technique.
Jakobs C; Kneer J; Martin D; Boulloche J; Brivet M; Poll-The BT; Saudubray JM
Eur J Pediatr; 1997 Aug; 156 Suppl 1():S78-82. PubMed ID: 9266222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
